A-443654 Inhibitor

Name: A-443654 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754454
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754454

A-443654 is a pan-Akt inhibitor. It has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

A-443654, Inhibitor

Full Product Name

A-443654

Product Gene Name

A-443654, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

397.47

Solubility

DMSO: 100mg/mL (251.59mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C24H23N5O

SMILES

N[C@H](COC1=CN=CC(C2=CC3=C(NN=C3C)C=C2)=C1)CC4=CNC5=CC=CC=C54

CAS Number

552325-16-3

Target & IC50

Akt1: ic50 160pM (ki)
Akt2: ic50 160pM (ki)
Akt3: ic50 160pM (ki)
PKA: ic50 6.3nM (ki)
RSK2: ic50 11nM (ki)
PKCgamma: ic50 24nM (ki)
CDK2: ic50 24nM (ki)
PKCdelta: ic50 33nM (ki)
GSK3beta: ic50 41nM (ki)
ERK2: ic50 340nM (ki)
cKIT: ic50 1.2uM (ki)
Chk1: ic50 2.3uM (ki)
CK2: ic50 2.4uM (ki)
SRC: ic50 2.6uM (ki)
KDR: ic50 3.1uM (ki)
MAPK-AP2: ic50 3.3uM (ki)
Flt1: ic50 3.6uM (ki)

In Vitro

A-443654 (7.5mg/kg/d, s.c.) inhibits tumor growth in the 3T3-Akt1 flank tumor model. A-443654 (50mg/kg, s.c.) induces apoptosis in 3T3-Akt1 flank tumors. A-443654 (30mg/kg, s.c.) leads to increased levels of phosphorylated Akt1 in MiaPaCa-2 tumors[1].

Product Categories/Family for A-443654, inhibitor

Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Protein Tyrosine Kinase/RTK

Product References and Citations for A-443654, inhibitor

Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005 Jun;4(6):977-86.
Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005 Jun;4(6):977-86.
Zheng J, et al. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 2010 Oct 1;296(1):74-87.
Zheng J, et al. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 2010 Oct 1;296(1):74-87.
Gallia GL, et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009 Feb;8(2):386-93.
Gallia GL, et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009 Feb;8(2):386-93.
Zhao Y, et al. Estrogen receptor alpha and beta regulate actin polymerization and spatial memory through an SRC-1/mTORC2-dependent pathway in the hippocampus of female mice. J Steroid Biochem Mol Biol. 2017 Nov;174:96-113.
Zhao Y, et al. Estrogen receptor alpha and beta regulate actin polymerization and spatial memory through an SRC-1/mTORC2-dependent pathway in the hippocampus of female mice. J Steroid Biochem Mol Biol. 2017 Nov;174:96-113.

Other Notes

Small volumes of A-443654, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for A-443654 purchase

MBS5754454 is an inhibitor targeting A-443654.